EpicentRx, Inc. Torrey Pines, California, USA
Short Communication
Sensitization of PD-1/L1 Refractory Lung Tumors in an Immunocompetent Mouse Model with AdAPT-001
Author(s): Chris Larson, Bryan Oronsky*, Scott Caroen, Jeannie Williams, Meaghan Stirn and Tony Reid
The reputation of checkpoint inhibitors as potential game changers in oncology is well-deserved as the the 14/14 complete responses recently
reported with the PD-1 inhibitor, dostarlimab, in mismatch repair (MMR) deficient locally advanced rectal cancer demonstrates but comes with
an important caveat: in most cases and in most cancers non-responders greatly outnumber responders. This begs the question of how to mimic
the unprecedented result with dostarlimab in MMR-proficient and otherwise checkpoint inhibitor non-responsive cancers. Several strategies to
sensitize tumors to checkpoint inhibitors are under active investigation. These include combinations with other checkpoint inhibitors, chemotherapy,
angiogenesis inhibitors, targeted agents, DNA damage repair inhibitors, epigenetic modifiers, and TGF-β inhibitors. This short communication
presents data on.. Read More»
DOI:
10.37421/2576-3857.2022.07.165
Journal of Oncology Medicine & Practice received 715 citations as per Google Scholar report
